Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Apple, Thermo Fisher, Royal Dutch Shell, Microsoft and Estee Lauder

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 21, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. (AAPL - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Royal Dutch Shell plc (RDS.A - Free Report) , Microsoft Corporation (MSFT - Free Report) and The Estée Lauder Companies Inc. (EL - Free Report) .

Here are highlights from Monday’s Analyst Blog:

Top Analyst Reports for Apple, Thermo Fisher and Royal Dutch Shell

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple, Thermo Fisher, and Royal Dutch Shell. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Apple have modestly underperformed the S&P 500 over the past year (+33.5% vs. +38.9%), but things have been improving for the tech giant lately. The Zacks analyst believes that the company has been benefiting from momentum in the Services business, strong adoption of Apple Pay and growing Apple Music subscriber base.

Apple’s near-term prospects remain bright and are driven by new iPhones that support 5G, revamped iPad and Mac line-up of devices, as well as an expanding App Store ecosystem. The company’s ability to attract small developers has been a key catalyst. Foreign exchange woes, lower than expected growth in the Services segment and supply constraints have been limiting the company’s growth though.

(You can read the full research report on Apple here >>>)

Thermo Fisher shares have gained +31.4% in the last six months against the Zacks Medical Instruments industry’s gain of +16.6%. The Zacks analyst believes that several takeovers such as the Advanced Bioprocessing buyout from BD and Patheon have been expanding the company’s growth profile. 

Thermo Fisher experienced strong end market growth in the second quarter, driven by robust fundamentals in the life sciences, and strong pandemic response. The company also raised 2021 guidance, which buoys optimism. Unfavorable macroeconomic conditions, a competitive landscape and currency fluctuations remain major headwinds though.

(You can read the full research report on Thermo Fisher here >>>)

Shares of Royal Dutch Shell have gained +0.9% in the past three months against the Zacks International Integrated Oil industry’s fall of -2.8%. The Zacks analyst believes that Royal Dutch Shell is poised for capital appreciation based on a slew of tailwinds. The BG acquisition has made Shell the largest liquefied natural gas producer in the world.

Shell’s announcement of the launch of a $2 billion stock buyback program reflects its steadily improving earnings. It is also making solid progress toward the transition to a renewable energy-focused future. The company is, however, facing some headwinds on the production front, which is evident from the amount of hydrocarbon it pumped in the first half. Its dismal reserve replacement ratio might restrict its production growth potential.

(You can read the full research report on Royal Dutch Shell here >>>)

Other noteworthy reports we are featuring today include Microsoft and The Estée Lauder Companies.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                          

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.